Trending...
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
- Chicago Creator Aaron Devere Unveils GOOBZ'D™, an Original Animated and Collectible Universe
NORTHBROOK, Ill.--(BUSINESS WIRE)--Endevica Bio, a company developing first-in-class peptide drug candidates with better safety and efficacy properties, announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for its lead investigational product, TCMCB07, allowing the company to proceed with initiating clinical studies. TCMCB07 is an investigational melanocortin‐4 antagonist peptide designed to treat cachexia in people that have cancer and other chronic diseases. Endevica Bio plans to initiate Phase 2 clinical studies in pancreatic cancer in 2Q 2023.
"The acceptance of the IND means that Endevica begins its next chapter on our quest to improve the lives of people who are suffering from the effects of cachexia. We have been so encouraged by the pre-clinical data on TCMCB07 that have been generated to date and are looking forward to the next phase of its development," said Russ Potterfield, CEO and Executive Chairman of Endevica.
More on illi News
"People with cachexia are suffering as their bodies can't adequately process the nutrients they need to survive. The current standard of care, appetite stimulants and corticosteroids, are not adequate in effectively mitigating this condition," said Daniel Marks M.D., Ph.D., Chief Medical Officer of Endevica. "TCMCB07 has a lot of promise in its ability to modulate the body's behavioral and metabolic response to chronic illness, and we are hopeful that it will be proven to be a safe and effective treatment option."
"We designed TCMCB07 to be a first-in-class peptide drug. We are confident that its ability to cross the blood-brain barrier and act on previously inaccessible target receptors will be profoundly beneficial for patient outcomes. This is just the first product in our pipeline of next-generation peptide therapeutics," said Kenneth Gruber Ph.D., Chief Scientific Officer and Founder of Endevica.
With the IND in place, Endevica will be finalizing its Phase 2a protocol for a multi-national trial, which is expected to generate robust data about this potentially life-saving compound.
More on illi News
About Endevica Bio
Endevica Bio was formed to create first-in-class peptide drug candidates that form an entirely new class of therapeutics. Endevica's technology platform, protected by a family of patents and pending applications, allows for the modification of peptides to modulate activity of G-protein coupled receptors behind the blood-brain barrier. Endevica's initial drug candidate, TCMCB07, is designed to treat cancer cachexia, which is the cause of death for up to 40% of cancer patients. More information can be found at www.endevicabio.com.
Contacts
Endevica Bio
LeAnn Kuhlmann Qi
Chief Commercial Officer
(573) 881-5080
"The acceptance of the IND means that Endevica begins its next chapter on our quest to improve the lives of people who are suffering from the effects of cachexia. We have been so encouraged by the pre-clinical data on TCMCB07 that have been generated to date and are looking forward to the next phase of its development," said Russ Potterfield, CEO and Executive Chairman of Endevica.
More on illi News
- Just Right Armrest Introduces an Adjustable Approach to Vehicle Arm Support
- Wig Floater Introduces a Convenient Magnetic Hanging Solution for Wig Storage
- Automated Mud Flap System Offers an Adjustable Approach to Heavy-Duty Vehicle Mud Flap Design
- Chicago: Mayor Brandon Johnson Announces City Has Made More Than $1 Billion in Supplemental Pension Payments Since 2023
- Chicago: Mayor Brandon Johnson, DPD Celebrate Completion of Winnslie Parkway Expansion in Ravenswood
"People with cachexia are suffering as their bodies can't adequately process the nutrients they need to survive. The current standard of care, appetite stimulants and corticosteroids, are not adequate in effectively mitigating this condition," said Daniel Marks M.D., Ph.D., Chief Medical Officer of Endevica. "TCMCB07 has a lot of promise in its ability to modulate the body's behavioral and metabolic response to chronic illness, and we are hopeful that it will be proven to be a safe and effective treatment option."
"We designed TCMCB07 to be a first-in-class peptide drug. We are confident that its ability to cross the blood-brain barrier and act on previously inaccessible target receptors will be profoundly beneficial for patient outcomes. This is just the first product in our pipeline of next-generation peptide therapeutics," said Kenneth Gruber Ph.D., Chief Scientific Officer and Founder of Endevica.
With the IND in place, Endevica will be finalizing its Phase 2a protocol for a multi-national trial, which is expected to generate robust data about this potentially life-saving compound.
More on illi News
- Chicago: Mayor Brandon Johnson Cuts Ribbon on Boulevard Apartments, Preserving 70 Affordable Homes Across Three Buildings
- Naperville: Structure Fire in the 30W000 Block of Argyll Lane
- Naperville's Annual Public Safety Open House Set for Sept. 26
- Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
- Canadian Tint Expo 2027: Why Every Window Tinter Should Compete in Niagara Falls on April 3rd & 4th
About Endevica Bio
Endevica Bio was formed to create first-in-class peptide drug candidates that form an entirely new class of therapeutics. Endevica's technology platform, protected by a family of patents and pending applications, allows for the modification of peptides to modulate activity of G-protein coupled receptors behind the blood-brain barrier. Endevica's initial drug candidate, TCMCB07, is designed to treat cancer cachexia, which is the cause of death for up to 40% of cancer patients. More information can be found at www.endevicabio.com.
Contacts
Endevica Bio
LeAnn Kuhlmann Qi
Chief Commercial Officer
(573) 881-5080
Filed Under: Business
0 Comments
Latest on illi News
- OnDemand Launches Craft Coffee and Pantry as the Next Step in Its Growing Amenity Platform
- Century Fasteners de Mexico Exhibiting at the 2026 Automotive & Aerospace Nearshoring Summit
- Northeast Airlines aligns with European Investment Group
- Retell AI White Label Platform for Agencies Launched by VoiceAIWrapper, With Branded Client Portals and No Per-Minute Markup
- FOCUS Names Mark Phillips Senior Vice President of Business Development
- STLE's Interactive Lubrication Training Experience Returns to Southwest Research Institute
- Notaron Expands Online Notarization Access Following Wisconsin Approval
- Mondo teams up with Paragon Sports Constructors as official outdoor track partner for Texas
- Exercise Scientist Turns a Personal Heart Scare into a Free Training Tool
- Wings Air Helicopters Selected to Support VIP Transportation for Resorts World in New York
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Houston This October
- Chicago: Mayor Brandon Johnson, Department of Technology and Innovation Launch Revamped Mayor's Office Website
- Chicago: Mayor Brandon Johnson, Department of Technology and Innovation Launch Revamped Mayor's Office Website
- The Social Capital Revolution Comes to Phoenix!
- Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
- Chicago: Mayor Brandon Johnson Joins Mayor Mamdani and Coalition of Cities and Counties in New York-Led Lawsuit Challenging Federal Public Charge Rule
- FBI/DoW plot uncovered to hurt Trump/Vance through encouraged "widespread" cybersecurity breaches and racketeering theft of $80m in USDA payments
- Bettingbladet releases H1 2026 report on the Swedish online gambling market
- Garage door installation or repair in Minnesota? Which makes more sense for your family?
- Midwest Pond Features Opens Fall Pond Installation Scheduling Across Chicagoland